CB-103 是口服具有活性的蛋白相互作用抑制剂，靶向NOTCH转录复合体，具有抗肿瘤作用。

CB-103 is a orally active inhibitor of notch signaling pathway, with anti-tumor activity.

CB-103 has shown the ability to block NOTCH signaling in human T cell acute lymphoblastic leukemia cancer cell lines, and?exhibits anti-tumor efficacy in GSI resistant T-ALL cell lines[2].

CB-103?inhibits growth of GSI/Mab resistant triple negative breast cancer, and?exhibits anti-tumor activity in xenograft models of human T-ALL and mouse mammary tumors[3].

218457-67-1

C15H18N2O

242.32

DMSO:230 mg/mL (949.16 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years